[1]
|
Stover, C.K., et al. (2000) Complete Genome Sequence of Pseudomonas aeruginosa PAO1, an Opportunistic Pathogen. Nature, 406, 959-964. https://doi.org/10.1038/35023079
|
[2]
|
Wong, S., et al. (2000) Recalls of Foods and Cos-metics Due to Microbial Contamination Reported to the U.S. Food and Drug Administration. Journal of Food Protec-tion, 63, 1113-1116. https://doi.org/10.4315/0362-028X-63.8.1113
|
[3]
|
Carson, L.A., et al. (1972) Factors Af-fecting Comparative Resistance of Naturally Occurring and Subcultured Pseudomonas aeruginosa to Disinfectants. Ap-plied Microbiology, 23, 863-869.
https://doi.org/10.1128/AEM.23.5.863-869.1972
|
[4]
|
Rahme, L.G., et al. (1995) Common Virulence Factors for Bacterial Pathogenicity in Plants and Animals. Science, 268, 1899-1902. https://doi.org/10.1126/science.7604262
|
[5]
|
Strateva, T., Y.D. (2009) Pseudomonas aeruginosa—A Phenome-non of Bacterial Resistance. Journal of Medical Microbiology, 58, 1133-1148. https://doi.org/10.1099/jmm.0.009142-0
|
[6]
|
van Delden, C. (2007) Pseudomonas aeruginosa Bloodstream In-fections: How Should We Treat Them? International Journal of Antimicrobial Agents, 30, S71-S75. https://doi.org/10.1016/j.ijantimicag.2007.06.015
|
[7]
|
Wisplinghoff, H., et al. (2004) Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clinical Infec-tious Diseases, 39, 309-317. https://doi.org/10.1086/421946
|
[8]
|
Page, M.G. and Heim, J. (2009) Prospects for the Next Anti-Pseudomonas Drug. Current Opinion in Pharmacology, 9, 558-565. https://doi.org/10.1016/j.coph.2009.08.006
|
[9]
|
Sarlangue, J., Brissaud, O. and Labreze, C. (2006) [Clinical Fea-tures of Pseudomonas aeruginosa Infections]. Archives de Pédiatrie, 13, S13-S16.
|
[10]
|
Franzetti, F., et al. (1992) Pseudomonas Infections in Patients with AIDS and AIDS-Related Complex. Journal of Internal Medicine, 231, 437-443. https://doi.org/10.1111/j.1365-2796.1992.tb00957.x
|
[11]
|
Lode, H., et al. (2000) Nosocomial Pneumo-nia: Epidemiology, Pathogenesis, Diagnosis, Treatment and Prevention. Current Opinion in Infectious Diseases, 13, 377-384. https://doi.org/10.1097/00001432-200008000-00009
|
[12]
|
Lyczak, J.B., Cannon, C.L. and Pier, G.B. (2000) Establishment of Pseudomonas aeruginosa Infection: Lessons from a Versatile Opportunist. Microbes and Infec-tion, 2, 1051-1060. https://doi.org/10.1016/S1286-4579(00)01259-4
|
[13]
|
Saltzstein, D., et al. (2007) Complicated Urinary Tract Infections Treated with Extended-Release Ciprofloxacin with Emphasis on Pseudomonas aeruginosa. Journal of Chemotherapy, 19, 694-702.
https://doi.org/10.1179/joc.2007.19.6.694
|
[14]
|
Thomas, P., et al. (1985) Pseudomonas Dermatitis Associated with a Swimming Pool. JAMA, 253, 1156-1159.
https://doi.org/10.1001/jama.1985.03350320080022
|
[15]
|
Fleiszig, S.M. and Evans, D.J. (2002) The Pathogenesis of Bacterial Keratitis: Studies with Pseudomonas aeruginosa. Clinical and Experimental Optometry, 85, 271-278. https://doi.org/10.1111/j.1444-0938.2002.tb03082.x
|
[16]
|
Hart, C.A. and Winstanley, C. (2002) Persistent and Aggressive Bacteria in the Lungs of Cystic Fibrosis Children. British Medical Bulletin, 61, 81-96. https://doi.org/10.1093/bmb/61.1.81
|
[17]
|
Pasteur, M.C., et al. (2010) British Thoracic Society Guideline for Non-CF Bronchiectasis. Thorax, 65, i1-i58.
|
[18]
|
Nichols, W.W., et al. (1988) Inhibition of Tobramycin Diffusion by Binding to Alginate. Antimicrobial Agents and Chemotherapy, 32, 518-523. https://doi.org/10.1128/AAC.32.4.518
|
[19]
|
Pages, J.M., James, C.E. and Winterhalter, M. (2008) The Porin and the Permeating Antibiotic: A Selective Diffusion Barrier in Gram-Negative Bacteria. Nature Reviews Microbiology, 6, 893-903. https://doi.org/10.1038/nrmicro1994
|
[20]
|
Lambert, P.A. (2002) Mechanisms of Antibiotic Resistance in Pseudomonas aeruginosa. Journal of the Royal Society of Medicine, 95, 22-26.
|
[21]
|
Piddock, L.J. (2006) Multi-drug-Resistance Efflux Pumps? Not Just for Resistance. Nature Reviews Microbiology, 4, 629-636. https://doi.org/10.1038/nrmicro1464
|
[22]
|
Coban, A.Y., Ekinci, B. and Durupinar, B. (2004) A Multidrug Efflux Pump Inhibitor Reduces Fluoroquinolone Resistance in Pseudomonas aeruginosa Isolates. Chemotherapy, 50, 22-26. https://doi.org/10.1159/000077280
|
[23]
|
Hocquet, D., et al. (2007) MexAB-OprM- and MexXY-Overproducing Mutants Are Very Prevalent among Clinical Strains of Pseudomonas aeruginosa with Reduced Susceptibility to Ti-carcillin. Antimicrobial Agents and Chemotherapy, 51, 1582-1583. https://doi.org/10.1128/AAC.01334-06
|
[24]
|
Sanchez, P., et al. (2002) Fitness of in Vitro Selected Pseudomonas aeruginosa nalB and nfxB Multidrug Resistant Mutants. Journal of Antimicrobial Chemotherapy, 50, 657-664. https://doi.org/10.1093/jac/dkf185
|
[25]
|
Masterton, R.G. and Turner, P.J. (2006) Trends in Antimicrobial Suscep-tibility in UK Centres: The MYSTIC Programme (1997-2002). International Journal of Antimicrobial Agents, 27, 69-72.
https://doi.org/10.1016/j.ijantimicag.2005.09.011
|
[26]
|
Bendig, J.W., et al. (1987) Two Neutropenic Patients with Multiple Resistant Pseudomonas aeruginosa Septicaemia Treated with Ciprofloxacin. Journal of the Royal Society of Medicine, 80, 316-317.
https://doi.org/10.1177/014107688708000521
|
[27]
|
Brazas, M.D. and Hancock, R.E. (2005) Ciprofloxacin Induc-tion of a Susceptibility Determinant in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 49, 3222-3227.
https://doi.org/10.1128/AAC.49.8.3222-3227.2005
|
[28]
|
Aaron, S.D., et al. (2002) Single and Combination Anti-biotic Susceptibilities of Planktonic, Adherent, and Biofilm-Grown Pseudomonas aeruginosa Isolates Cultured from Sputa of Adults with Cystic Fibrosis. Journal of Clinical Microbiology, 40, 4172-4179. https://doi.org/10.1128/JCM.40.11.4172-4179.2002
|
[29]
|
Kohler, T., et al. (1997) Characterization of MexE-MexF-OprN, a Positively Regulated Multidrug Efflux System of Pseudomonas aeruginosa. Molecular Microbi-ology, 23, 345-354. https://doi.org/10.1046/j.1365-2958.1997.2281594.x
|
[30]
|
Bateman, F.L., et al. (2012) Bio-logical Efficacy and Stability of Diluted Ticarcillin-Clavulanic Acid in the Topical Treatment of Pseudomonas aeruginosa Infections. Veterinary Dermatology, 23, 97-e22.
https://doi.org/10.1111/j.1365-3164.2011.01018.x
|
[31]
|
Theuretzbacher, U. (2009) Future Antibiotics Scenarios: Is the Tide Starting to Turn? International Journal of Antimicrobial Agents, 34, 15-20. https://doi.org/10.1016/j.ijantimicag.2009.02.005
|
[32]
|
Srinivas, N., et al. (2010) Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa. Science, 327, 1010-1013. https://doi.org/10.1126/science.1182749
|
[33]
|
Mesaros, N., et al. (2007) Pseudomonas aeruginosa: Resistance and Therapeutic Options at the Turn of the New Millennium. Clinical Microbiology and Infection, 13, 560-578. https://doi.org/10.1111/j.1469-0691.2007.01681.x
|
[34]
|
Hoiby, N., Ciofu, O. and Bjarnsholt, T. (2010) Pseudo-monas aeruginosa Biofilms in Cystic Fibrosis. Future Microbiology, 5, 1663-1674. https://doi.org/10.2217/fmb.10.125
|
[35]
|
Werner, E., et al. (2004) Stratified Growth in Pseudomonas aeruginosa Biofilms. Applied and Environmental Microbiology, 70, 6188-6196. https://doi.org/10.1128/AEM.70.10.6188-6196.2004
|
[36]
|
Moreau-Marquis, S., Stanton, B.A. and O’Toole, G.A. (2008) Pseudomonas aeruginosa Biofilm Formation in the Cystic Fibrosis Airway. Pulmonary Pharmacology and Therapeutics, 21, 595-599.
https://doi.org/10.1016/j.pupt.2007.12.001
|
[37]
|
Whiteley, M., et al. (2001) Gene Expression in Pseudomonas ae-ruginosa Biofilms. Nature, 413, 860-864.
https://doi.org/10.1038/35101627
|
[38]
|
Hoffmann, N., et al. (2005) Novel Mouse Model of Chronic Pseudomonas aeruginosa Lung Infection Mimicking Cystic Fibrosis. Infection and Immunity, 73, 2504-2514. https://doi.org/10.1128/IAI.73.4.2504-2514.2005
|
[39]
|
Hoiby, N., et al. (2011) The Clinical Impact of Bacterial Biofilms. International Journal of Oral Science, 3, 55-65.
|
[40]
|
Tielker, D., et al. (2005) Pseudomonas aeruginosa lec-tin LecB Is Located in the Outer Membrane and Is Involved in Biofilm Formation. Microbiology, 151, 1313-1323. https://doi.org/10.1099/mic.0.27701-0
|
[41]
|
McIver, K., Kessler, E. and Ohman, D.E. (1991) Substitution of Ac-tive-Site His-223 in Pseudomonas aeruginosa Elastase and Expression of the Mutated lasB Alleles in Escherichia coli Show Evidence for Autoproteolytic Processing of Proelastase. Journal of Bacteriology, 173, 7781-7789. https://doi.org/10.1128/JB.173.24.7781-7789.1991
|
[42]
|
Johansson, E.M., et al. (2008) Inhibition and Dispersion of Pseudomonas aeruginosa Biofilms by Glycopeptide Dendrimers Targeting the Fucose-Specific Lectin LecB. Chemi-cal Biology, 15, 1249-1257.
https://doi.org/10.1016/j.chembiol.2008.10.009
|
[43]
|
von Bismarck, P., Schneppenheim, R. and Schumacher, U. (2001) Successful Treatment of Pseudomonas aeruginosa Respiratory Tract Infection with a Sugar Solution—A Case Report on a Lectin Based Therapeutic Principle. Klinische Pädiatrie, 213, 285-287. https://doi.org/10.1055/s-2001-17220
|
[44]
|
Doggett, R.G., Harrison, G.M. and Wallis, E.S. (1964) Comparison of Some Properties of Pseudomonas aeruginosa Isolated from Infections in Persons with and without Cystic Fibrosis. Journal of Bacteriology, 87, 427-431.
https://doi.org/10.1128/JB.87.2.427-431.1964
|
[45]
|
Cobb, L.M., et al. (2004) Pseudomonas aeruginosa Flagellin and Alginate Elicit Very Distinct Gene Expression Patterns in Airway Epithelial Cells: Implications for Cystic Fibrosis Disease. The Journal of Immunology, 173, 5659-5670.
https://doi.org/10.4049/jimmunol.173.9.5659
|
[46]
|
Simpson, J.A., Smith, S.E. and Dean, R.T. (1989) Scavenging by Alginate of Free Radicals Released by Macrophages. Free Radical Biology and Medicine, 6, 347-353. https://doi.org/10.1016/0891-5849(89)90078-6
|
[47]
|
Alipour, M., Suntres, Z.E. and Omri, A. (2009) Importance of DNase and Alginate Lyase for Enhancing Free and Liposome Encapsulated Aminoglycoside Activity against Pseu-domonas aeruginosa. Journal of Antimicrobial Chemotherapy, 64, 317-325. https://doi.org/10.1093/jac/dkp165
|
[48]
|
Alkawash, M.A., Soothill, J.S. and Schiller, N.L. (2006) Alginate Lyase Enhances Antibiotic Killing of Mucoid Pseudomonas aeruginosa in Biofilms. APMIS, 114, 131-138. https://doi.org/10.1111/j.1600-0463.2006.apm_356.x
|
[49]
|
Bayer, A.S., et al. (1992) Effects of Alginase on the Natural History and Antibiotic Therapy of Experimental Endocarditis Caused by Mucoid Pseudomonas aeruginosa. In-fection and Immunity, 60, 3979-3985.
https://doi.org/10.1128/IAI.60.10.3979-3985.1992
|
[50]
|
Lamppa, J.W., et al. (2011) Genetically Engineered Algi-nate Lyase-PEG Conjugates Exhibit Enhanced Catalytic Function and Reduced Immunoreactivity. PLoS ONE, 6, e17042. https://doi.org/10.1371/journal.pone.0017042
|
[51]
|
Sudarsan, N., et al. (2008) Riboswitches in Eubacteria Sense the Second Messenger Cyclic di-GMP. Science, 321, 411-413. https://doi.org/10.1126/science.1159519
|
[52]
|
An-toniani, D., et al. (2010) Monitoring of Diguanylate Cyclase Activity and of Cyclic-di-GMP Biosynthesis by Whole-Cell Assays Suitable for High-Throughput Screening of Biofilm Inhibitors. Applied Microbiology and Biotechnology, 85, 1095-1104. https://doi.org/10.1007/s00253-009-2199-x
|
[53]
|
Ueda, A., et al. (2009) Uracil Influences Quorum Sensing and Biofilm Formation in Pseudomonas aeruginosa and Fluorouracil Is an Antagonist. Microbial Biotechnolo-gy, 2, 62-74. https://doi.org/10.1111/j.1751-7915.2008.00060.x
|
[54]
|
Landini, P., et al. (2010) Molecular Mecha-nisms of Compounds Affecting Bacterial Biofilm Formation and Dispersal. Applied Microbiology and Biotechnology, 86, 813-823. https://doi.org/10.1007/s00253-010-2468-8
|
[55]
|
Sauer, K., et al. (2004) Characterization of Nutri-ent-Induced Dispersion in Pseudomonas aeruginosa PAO1 Biofilm. Journal of Bacteriology, 186, 7312-7326. https://doi.org/10.1128/JB.186.21.7312-7326.2004
|
[56]
|
Thormann, K.M., et al. (2005) Induction of Rapid De-tachment in Shewanella oneidensis MR-1 Biofilms. Journal of Bacteriology, 187, 1014-1021. https://doi.org/10.1128/JB.187.3.1014-1021.2005
|
[57]
|
Barraud, N., et al. (2009) Nitric Oxide Signaling in Pseu-domonas aeruginosa Biofilms Mediates Phosphodiesterase Activity, Decreased Cyclic di-GMP Levels, and Enhanced Dispersal. Journal of Bacteriology, 191, 7333-7342.
https://doi.org/10.1128/JB.00975-09
|
[58]
|
Davies, D.G. and Marques, C.N. (2009) A Fatty Acid Messenger Is Responsible for Inducing Dispersion in Microbial Biofilms. Journal of Bacteriology, 191, 1393-1403. https://doi.org/10.1128/JB.01214-08
|
[59]
|
Rice, S.A., et al. (2009) The Biofilm Life Cycle and Virulence of Pseu-domonas aeruginosa Are Dependent on a Filamentous Prophage. The ISME Journal, 3, 271-282. https://doi.org/10.1038/ismej.2008.109
|
[60]
|
Sintim, H.O., et al. (2010) Paradigm Shift in Discovering Next-Generation Anti-Infective Agents: Targeting Quorum Sensing, c-di-GMP Signaling and Biofilm Formation in Bacteria with Small Molecules. Future Medicinal Chemistry, 2, 1005-1035. https://doi.org/10.4155/fmc.10.185
|
[61]
|
Wu, H., et al. (2011) Effects of Ginseng on Pseudomonas aeruginosa Motility and Biofilm Formation. FEMS Immunology and Medical Microbiology, 62, 49-56. https://doi.org/10.1111/j.1574-695X.2011.00787.x
|
[62]
|
Dean, S.N., Bishop, B.M. and van Hoek, M.L. (2011) Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: D-Enantiomer of LL-37. Frontiers in Mi-crobiology, 2, 128.
https://doi.org/10.3389/fmicb.2011.00128
|
[63]
|
Eckert, R. (2011) Road to Clinical Efficacy: Challenges and Novel Strategies for Antimicrobial Peptide Development. Frontiers in Microbiology, 6, 635-651. https://doi.org/10.2217/fmb.11.27
|
[64]
|
Lambert, C., et al. (2011) Predatory Bdellovibrio Bacteria Use Gliding Motility to Scout for Prey on Surfaces. Journal of Bacteriology, 193, 3139-3141. https://doi.org/10.1128/JB.00224-11
|
[65]
|
Atterbury, R.J., et al. (2011) Effects of Orally Administered Bdellovib-rio bacteriovorus on the Well-Being and Salmonella Colonization of Young Chicks. Applied and Environmental Micro-biology, 77, 5794-5803.
https://doi.org/10.1128/AEM.00426-11
|
[66]
|
Dashiff, A., et al. (2011) Predation of Human Pathogens by the Predatory Bacteria Micavibrio aeruginosavorus and Bdellovibrio bacteriovorus. Journal of Applied Microbiology, 110, 431-444.
https://doi.org/10.1111/j.1365-2672.2010.04900.x
|
[67]
|
Girard, G. and Bloemberg, G.V. (2008) Central Role of Quorum Sensing in Regulating the Production of Pathogenicity Factors in Pseudomonas aeruginosa. Future Microbiol-ogy, 3, 97-106. https://doi.org/10.2217/17460913.3.1.97
|
[68]
|
Winstanley, C. and Fothergill, J.L. (2009) The Role of Quorum Sensing in Chronic Cystic Fibrosis Pseudomonas aeruginosa Infections. FEMS Microbiology Letters, 290, 1-9. https://doi.org/10.1111/j.1574-6968.2008.01394.x
|
[69]
|
Schuster, M., et al. (2003) Identification, Timing, and Signal Specificity of Pseudomonas aeruginosa Quorum-Controlled Genes: A Transcriptome Analysis. Journal of Bac-teriology, 185, 2066-2079.
https://doi.org/10.1128/JB.185.7.2066-2079.2003
|
[70]
|
Wagner, V.E. and Iglewski, B.H. (2008) P. aeruginosa Biofilms in CF Infection. Clinical Reviews in Allergy & Immunology, 35, 124-134. https://doi.org/10.1007/s12016-008-8079-9
|
[71]
|
Latifi, A., et al. (1996) A Hierarchical Quorum-Sensing Cascade in Pseudomonas aeruginosa Links the Transcriptional Activators LasR and RhIR (VsmR) to Expression of the Station-ary-Phase Sigma Factor RpoS. Molecular Microbiology, 1, 1137-1146. https://doi.org/10.1046/j.1365-2958.1996.00063.x
|
[72]
|
Davies, D.G., et al. (1998) The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm. Science, 280, 295-298. https://doi.org/10.1126/science.280.5361.295
|
[73]
|
Juhas, M., et al. (2005) GeneChip Expression Analysis of the VqsR Regulon of Pseudomonas aeruginosa TB. FEMS Microbiology Letters, 242, 287-295. https://doi.org/10.1016/j.femsle.2004.11.020
|
[74]
|
Bjarnsholt, T., et al. (2005) Pseudomonas aeruginosa Tolerance to Tobramycin, Hydrogen Peroxide and Polymorphonuclear Leukocytes Is Quorum-Sensing Dependent. Microbiology, 151, 373-383.
https://doi.org/10.1099/mic.0.27463-0
|
[75]
|
Bjarnsholt, T., et al. (2005) Garlic Blocks Quorum Sensing and Pro-motes Rapid Clearing of Pulmonary Pseudomonas aeruginosa Infections. Microbiology, 151, 3873-3880. https://doi.org/10.1099/mic.0.27955-0
|
[76]
|
Wu, H., et al. (2004) Synthetic Furanones Inhibit Quorum-Sensing and Enhance Bacterial Clearance in Pseudomonas aeruginosa Lung Infection in Mice. Journal of Antimicrobial Chemo-therapy, 53, 1054-1061.
https://doi.org/10.1093/jac/dkh223
|
[77]
|
Hoffmann, N., et al. (2007) Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomo-nas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr−/− Mice. Antimicrobial Agents and Chem-otherapy, 51, 3677-3687.
https://doi.org/10.1128/AAC.01011-06
|
[78]
|
Moriarty, T.F., et al. (2007) Sputum Antibiotic Concentrations: Im-plications for Treatment of Cystic Fibrosis Lung Infection. Pediatric Pulmonology, 42, 1008-1017. https://doi.org/10.1002/ppul.20671
|
[79]
|
Gooderham, W.J. and Hancock, R.E. (2009) Regulation of Virulence and Antibiotic Resistance by Two-Component Regulatory Systems in Pseudomonas aeruginosa. FEMS Microbiology Re-views, 33, 279-294.
https://doi.org/10.1111/j.1574-6976.2008.00135.x
|
[80]
|
Chauhan, N. and Calderone, R. (2008) Two-Component Signal Transduction Proteins as Potential Drug Targets in Medically Important Fungi. Infection and Immunity, 76, 4795-4803. https://doi.org/10.1128/IAI.00834-08
|
[81]
|
Gotoh, Y., et al. (2010) Two-Component Signal Transduc-tion as Potential Drug Targets in Pathogenic Bacteria. Current Opinion in Microbiology, 13, 232-239. https://doi.org/10.1016/j.mib.2010.01.008
|
[82]
|
Lee, V.T., et al. (2005) Activities of Pseudomonas aeruginosa Ef-fectors Secreted by the Type III Secretion System in Vitro and during Infection. Infection and Immunity, 73, 1695-1705. https://doi.org/10.1128/IAI.73.3.1695-1705.2005
|
[83]
|
Goure, J., et al. (2005) Protective Anti-V Antibodies In-hibit Pseudomonas and Yersinia Translocon Assembly within Host Membranes. The Journal of Infectious Diseases, 192, 218-225. https://doi.org/10.1086/430932
|
[84]
|
Frank, D.W., et al. (2002) Generation and Characterization of a Protective Monoclonal Antibody to Pseudomonas aeruginosa PcrV. The Journal of Infectious Diseases, 186, 64-73. https://doi.org/10.1086/341069
|
[85]
|
Meyer, J.M., et al. (1996) Pyoverdin Is Essential for Virulence of Pseudo-monas aeruginosa. Infection and Immunity, 64, 518-523. https://doi.org/10.1128/IAI.64.2.518-523.1996
|
[86]
|
Lamont, I.L., et al. (2002) Siderophore-Mediated Signaling Regulates Virulence Factor Production in Pseudomonas aeruginosa. Proceedings of the National Academy of Sciences of the United States of America, 99, 7072-7077.
https://doi.org/10.1073/pnas.092016999
|
[87]
|
Halwani, M., et al. (2008) Co-Encapsulation of Gallium with Gen-tamicin in Liposomes Enhances Antimicrobial Activity of Gentamicin against Pseudomonas aeruginosa. Journal of An-timicrobial Chemotherapy, 62, 1291-1297.
https://doi.org/10.1093/jac/dkn422
|
[88]
|
Michel-Briand, Y. and Baysse, C. (2002) The Pyocins of Pseudomonas aeruginosa. Biochimie, 84, 499-510.
https://doi.org/10.1016/S0300-9084(02)01422-0
|
[89]
|
Filiatrault, M.J., Munson Jr., R.S. and Campagnari, A.A. (2001) Genetic Analysis of a Pyocin-Resistant Lipooligosaccharide (LOS) Mutant of Haemophilus ducreyi: Restoration of Full-Length LOS Restores Pyocin Sensitivity. Journal of Bacteriology, 183, 5756-5761. https://doi.org/10.1128/JB.183.19.5756-5761.2001
|
[90]
|
Bakkal, S., et al. (2010) Role of Bacteriocins in Mediat-ing Interactions of Bacterial Isolates Taken from Cystic Fibrosis Patients. Microbiology, 156, 2058-2067. https://doi.org/10.1099/mic.0.036848-0
|
[91]
|
Govan, J.R. (1986) In Vivo Significance of Bacteriocins and Bacteri-ocin Receptors. Scandinavian Journal of Infectious Diseases, 49, 31-37.
|
[92]
|
Scholl, D. and Martin Jr., D.W. (2008) Antibacterial Efficacy of R-Type Pyocins towards Pseudomonas aeruginosa in a Murine Peritonitis Model. Antimicro-bial Agents and Chemotherapy, 52, 1647-1652.
https://doi.org/10.1128/AAC.01479-07
|
[93]
|
Line, J.E., et al. (2008) Isolation and Purification of Enterocin E-760 with Broad Antimicrobial Activity against Gram-Positive And Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 52, 1094-1100.
https://doi.org/10.1128/AAC.01569-06
|
[94]
|
Cherif, A., et al. (2003) Detection and Characterization of the Novel Bacteriocin Entomocin 9, and Safety Evaluation of Its Producer, Bacillus thuringiensis ssp. entomocidus HD9. Journal of Applied Microbiology, 95, 990-1000.
https://doi.org/10.1046/j.1365-2672.2003.02089.x
|
[95]
|
Ling, H., et al. (2010) A Predicted S-Type Pyocin Shows a Bactericidal Activity against Clinical Pseudomonas aeruginosa Isolates through Membrane Damage. FEBS Letters, 584, 3354-3358.
https://doi.org/10.1016/j.febslet.2010.06.021
|
[96]
|
Montalban-Lopez, M., et al. (2011) Are Bacteriocins Underex-ploited? Novel Applications for Old Antimicrobials. Current Pharmaceutical Biotechnology, 12, 1205-1220. https://doi.org/10.2174/138920111796117364
|
[97]
|
Corr, S.C., Hill, C. and Gahan, C.G. (2009) Understanding the Mechanisms by Which Probiotics Inhibit Gastrointestinal Pathogens. Advances in Food and Nutrition Research, 56, 1-15. https://doi.org/10.1016/S1043-4526(08)00601-3
|
[98]
|
Denayer, S., Matthijs, S. and Cornelis, P. (2007) Pyocin S2 (Sa) Kills Pseudomonas aeruginosa Strains via the FpvA Type I Ferripyoverdine Receptor. Journal of Bacte-riology, 189, 7663-7668. https://doi.org/10.1128/JB.00992-07
|
[99]
|
Harper, D.R. and Enright, M.C. (2011) Bacte-riophages for the Treatment of Pseudomonas aeruginosa Infections. Journal of Applied Microbiology, 111, 1-7. https://doi.org/10.1111/j.1365-2672.2011.05003.x
|
[100]
|
Levin, B.R. and Bull, J.J. (2004) Population and Evolu-tionary Dynamics of Phage Therapy. Nature Reviews Microbiology, 2, 166-173. https://doi.org/10.1038/nrmicro822
|
[101]
|
Cooper, C.J., Denyer, S.P. and Maillard, J.Y. (2011) Rapid and Quantita-tive Automated Measurement of Bacteriophage Activity against Cystic Fibrosis Isolates of Pseudomonas aeruginosa. Journal of Applied Microbiology, 110, 631-640.
https://doi.org/10.1111/j.1365-2672.2010.04928.x
|
[102]
|
Hanlon, G.W., et al. (2001) Reduction in Exopolysaccha-ride Viscosity as an Aid to Bacteriophage Penetration through Pseudomonas aeruginosa Biofilms. Applied and Envi-ronmental Microbiology, 67, 2746-2753.
https://doi.org/10.1128/AEM.67.6.2746-2753.2001
|
[103]
|
Fu, W., et al. (2000) Bacteriophage Cocktail for the Pre-vention of Biofilm Formation by Pseudomonas aeruginosa on Catheters in an in Vitro Model System. Antimicrobial Agents and Chemotherapy, 54, 397-404.
https://doi.org/10.1128/AAC.00669-09
|
[104]
|
Debarbieux, L., et al. (2010) Bacteriophages Can Treat and Prevent Pseudomonas aeruginosa Lung Infections. The Journal of Infectious Diseases, 201, 1096-1104. https://doi.org/10.1086/651135
|
[105]
|
Morello, E., et al. (2011) Pulmonary Bacteriophage Therapy on Pseudomo-nas aeruginosa Cystic Fibrosis Strains: First Steps towards Treatment and Prevention. PLoS ONE, 6, e16963. https://doi.org/10.1371/journal.pone.0016963
|
[106]
|
Hawkins, C., et al. (2010) Topical Treatment of Pseudomonas aeruginosa otitis of Dogs with a Bacteriophage Mixture: A before/after Clinical Trial. Veterinary Microbiology, 146, 309-313.
https://doi.org/10.1016/j.vetmic.2010.05.014
|
[107]
|
Wright, A., et al. (2009) A Controlled Clinical Trial of a Thera-peutic Bacteriophage Preparation in Chronic Otitis Due to Antibiotic-Resistant Pseudomonas aeruginosa; a Preliminary Report of Efficacy. Clinical Otolaryngology, 34, 349- 357. https://doi.org/10.1111/j.1749-4486.2009.01973.x
|
[108]
|
Golshahi, L., et al. (2011) In Vitro Lung Delivery of Bac-teriophages KS4-M and PhiKZ Using Dry Powder Inhalers for Treatment of Burkholderia cepacia Complex and Pseu-domonas aeruginosa Infections in Cystic Fibrosis. Journal of Applied Microbiology, 110, 106-117. https://doi.org/10.1111/j.1365-2672.2010.04863.x
|
[109]
|
Lu, T.K. and Collins, J.J. (2007) Dispersing Biofilms with Engineered Enzymatic Bacteriophage. Proceedings of the National Academy of Sciences of the United States of America, 104, 11197-11202.
https://doi.org/10.1073/pnas.0704624104
|
[110]
|
Lu, T.K. and Collins, J.J. (2009) Engineered Bacteriophage Tar-geting Gene Networks as Adjuvants for Antibiotic Therapy. Proceedings of the National Academy of Sciences of the United States of America, 106, 4629-4634.
https://doi.org/10.1073/pnas.0800442106
|
[111]
|
Hagens, S., et al. (2004) Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage. Antimicrobial Agents and Chemotherapy, 48, 3817-3822.
https://doi.org/10.1128/AAC.48.10.3817-3822.2004
|
[112]
|
Borysowski, J., Weber-Dabrowska, B. and Gorski, A. (2006) Bacteriophage Endolysins as a Novel Class of Antibacterial Agents. Experimental Biology and Medicine (May-wood), 231, 366-377.
https://doi.org/10.1177/153537020623100402
|
[113]
|
Nelson, D., Loomis, L. and Fischetti, V.A. (2001) Prevention and Elimination of Upper Respiratory Colonization of Mice by Group A Streptococci by Using a Bacteriophage Lytic Enzyme. Proceedings of the National Academy of Sci- ences of the United States of America, 98, 4107-4112. https://doi.org/10.1073/pnas.061038398
|
[114]
|
Briers, Y., Walmagh, M. and Lavigne, R. (2011) Use of Bacterio-phage Endolysin EL188 and Outer Membrane Permeabilizers against Pseudomonas aeruginosa. Journal of Applied Mi-crobiology, 110, 778-785.
https://doi.org/10.1111/j.1365-2672.2010.04931.x
|
[115]
|
Rashel, M., et al. (2007) Efficient Elimination of Multi-drug-Resistant Staphylococcus aureus by Cloned Lysin Derived from Bacteriophage phiMR11. The Journal of Infec-tious Diseases, 196, 1237-1247. https://doi.org/10.1086/521305
|
[116]
|
Fischetti, V.A. (2008) Bacteriophage Lysins as Effective Antibacterials. Current Opinion in Microbiology, 11, 393- 400. https://doi.org/10.1016/j.mib.2008.09.012
|
[117]
|
Doring, G. and Pier, G.B. (2008) Vaccines and Immunotherapy against Pseudomonas aeruginosa. Vaccine, 26, 1011- 1024. https://doi.org/10.1016/j.vaccine.2007.12.007
|
[118]
|
Pennington, J.E., et al. (1975) Use of a Pseudomonas aeru-ginosa Vaccine in Patients with Acute Leukemia and Cystic Fibrosis. The American Journal of Medicine, 58, 629-636. https://doi.org/10.1016/0002-9343(75)90498-2
|
[119]
|
Cryz Jr., S.J., et al. (1991) Clinical Evaluation of an Octava-lent Pseudomonas aeruginosa Conjugate Vaccine in Plasma Donors and in Bone Marrow Transplant and Cystic Fibro-sis Patients. Antibiotics and Chemotherapy, 44, 157-162.
https://doi.org/10.1159/000420310
|
[120]
|
Lang, A.B., et al. (2004) Vaccination of Cystic Fibrosis Patients against Pseudomonas aeruginosa Reduces the Proportion of Patients Infected and Delays Time to Infection. The Pediatric Infec-tious Disease Journal, 23, 504-510.
https://doi.org/10.1097/01.inf.0000129688.50588.ac
|
[121]
|
Doring, G., et al. (2007) A Double-Blind Randomized Placebo-Controlled Phase III Study of a Pseudomonas aeruginosa Flagella Vaccine in Cystic Fibrosis Patients. Pro-ceedings of the National Academy of Sciences of the United States of America, 104, 11020-11025. https://doi.org/10.1073/pnas.0702403104
|
[122]
|
Palliyil, S. and Broadbent, I.D. (2009) Novel Immunotherapeutic Approaches to the Treatment of Infections Caused by Gram-Negative Bacteria. Current Opinion in Pharmacology, 9, 566-570. https://doi.org/10.1016/j.coph.2009.07.007
|
[123]
|
Baer, M., et al. (2009) An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity. Infection and Immunity, 77, 1083-1090.
https://doi.org/10.1128/IAI.00815-08
|
[124]
|
Faezi, S., et al. (2011) Passive Immunisation against Pseudomonas aeruginosa Recombinant Flagellin in an Experimental Model of Burn Wound Sepsis. Burns, 37, 865-872. https://doi.org/10.1016/j.burns.2010.12.003
|
[125]
|
Moskwa, P., et al. (2007) A Novel Host Defense System of Airways Is Defective in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 175, 174-183. https://doi.org/10.1164/rccm.200607-1029OC
|
[126]
|
Woodford, N., Wareham, D.W. and U.K.A.A.S. Group (2009) Tackling Antibiotic Resistance: A Dose of Common Antisense? Journal of Antimicrobial Chemotherapy, 63, 225-229. https://doi.org/10.1093/jac/dkn467
|
[127]
|
Bai, H., et al. (2010) Antisense Antibiotics: A Brief Review of Novel Target Discovery and Delivery. Current Drug Discovery Technologies, 7, 76-85. https://doi.org/10.2174/157016310793180594
|
[128]
|
Metzker, M.L. (2010) Sequencing Technologies—The Next Generation. Nature Reviews Genetics, 11, 31-46.
https://doi.org/10.1038/nrg2626
|
[129]
|
Winsor, G.L., et al. (2009) Pseudomonas Genome Database: Facilitating User-Friendly, Comprehensive Comparisons of Microbial Genomes. Nucleic Acids Research, 37, D483-D488. https://doi.org/10.1093/nar/gkn861
|
[130]
|
O’Carroll, M.R., et al. (2004) Clonal Strains of Pseudomonas aeruginosa in Paediatric and Adult Cystic Fibrosis Units. European Respiratory Society, 24, 101-106. https://doi.org/10.1183/09031936.04.00122903
|
[131]
|
Winstanley, C., et al. (2009) Newly Introduced Genomic Prophage Islands Are Critical Determinants of in Vivo Competitiveness in the Liverpool Epidemic Strain of Pseudomo-nas aeruginosa. Genome Research, 19, 12-23.
https://doi.org/10.1101/gr.086082.108
|
[132]
|
Parsons, Y.N., et al. (2002) Use of Subtractive Hybridization to Iden-tify a Diagnostic Probe for a Cystic Fibrosis Epidemic Strain of Pseudomonas aeruginosa. Journal of Clinical Microbi-ology, 40, 4607-4611.
https://doi.org/10.1128/JCM.40.12.4607-4611.2002
|
[133]
|
Mowat, E., et al. (2011) Pseudomonas aeruginosa Pop-ulation Diversity and Turnover in Cystic Fibrosis Chronic Infections. American Journal of Respiratory and Critical Care Medicine, 183, 1674-1679.
https://doi.org/10.1164/rccm.201009-1430OC
|
[134]
|
Armougom, F., et al. (2009) Microbial Diversity in the Spu-tum of a Cystic Fibrosis Patient Studied with 16S rDNA Pyrosequencing. European Journal of Clinical Microbiology & Infectious Diseases, 28, 1151-1154.
https://doi.org/10.1007/s10096-009-0749-x
|
[135]
|
Caporaso, J.G., et al. (2011) Moving Pictures of the Human Mi-crobiome. Genome Biology, 12, Article No. R50.
https://doi.org/10.1186/gb-2011-12-5-r50
|
[136]
|
Tunney, M.M., et al. (2008) Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medi-cine, 177, 995-1001.
https://doi.org/10.1164/rccm.200708-1151OC
|
[137]
|
Cox, M.J., et al. (2010) Airway Microbiota and Pathogen Abundance in Age-Stratified Cystic Fibrosis Patients. PLoS ONE, 5, e11044. https://doi.org/10.1371/journal.pone.0011044
|